Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4931 Comments
1168 Likes
1
Choice
Consistent User
2 hours ago
{协议答案}
👍 131
Reply
2
Keylanie
Active Reader
5 hours ago
{协议答案}
👍 225
Reply
3
Khaleed
Loyal User
1 day ago
{协议答案}
👍 284
Reply
4
Dezire
Trusted Reader
1 day ago
{协议答案}
👍 82
Reply
5
Maurine
Registered User
2 days ago
{协议答案}
👍 97
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.